Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica. - Wikidata - awgldk - TriplyDB

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.

http://www.wikidata.org/entity/Q34621516

about

Interferon-β-related tumefactive brain lesion in a Caucasian patient with neuromyelitis optica and clinical stabilization with tocilizumab Change in autoantibody and cytokine responses during the evolution of neuromyelitis optica in patients with systemic lupus erythematosus: A preliminary study Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab Aquaporin 4 and neuromyelitis optica The Immunology of Neuromyelitis Optica-Current Knowledge, Clinical Implications, Controversies and Future Perspectives Hypersensitivity Responses in the Central Nervous System Update on biomarkers in neuromyelitis optica Challenges and opportunities in designing clinical trials for neuromyelitis optica Molecular pathogenesis of neuromyelitis optica Treatment of neuromyelitis optica: state-of-the-art and emerging therapies Differential Plasma-cell evolution is linked with Dermatophagoides pteronyssinus immunotherapy response.Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders.Clinical spectrum and treatment of neuromyelitis optica spectrum disorders: evolution and current status.Neuromyelitis optica: clinical features, immunopathogenesis and treatment.Seronegative Neuromyelitis Optica Spectrum--the challenges on disease definition and pathogenesis.Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later.CNS Aquaporin-4-specific B cells connect with multiple B-cell compartments in neuromyelitis optica spectrum disorder.Aquaporins: important but elusive drug targets.Anti-N-Methyl-D-aspartate Receptor Encephalitis: A Severe, Potentially Reversible Autoimmune Encephalitis.Low levels of vitamin D in neuromyelitis optica spectrum disorder: association with disease disability.Cerebrospinal fluid aquaporin-4 antibody levels in neuromyelitis optica attacks.IL-6 in inflammation, immunity, and disease The treatment of neuromyelitis optica.Human immunoglobulin G reduces the pathogenicity of aquaporin-4 autoantibodies in neuromyelitis optica CD19 as a molecular target in CNS autoimmunity.Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS).Plasmablasts as migratory IgG-producing cells in the pathogenesis of neuromyelitis optica Expansion of CD27high plasmablasts in transverse myelitis patients that utilize VH4 and JH6 genes and undergo extensive somatic hypermutation.Treatment of neuromyelitis optica/neuromyelitis optica spectrum disorders with methotrexate B lymphocytes in neuromyelitis optica Neuromyelitis optica: an antibody-mediated disorder of the central nervous system.IL-6 contributes to an immune tolerance checkpoint in post germinal center B cells.Experimental Neuromyelitis Optica Induces a Type I Interferon Signature in the Spinal Cord.Severely exacerbated neuromyelitis optica rat model with extensive astrocytopathy by high affinity anti-aquaporin-4 monoclonal antibody.Inflammatory mediators alter the astrocyte transcriptome and calcium signaling elicited by multiple G-protein-coupled receptors.Present and Future Therapies in Neuromyelitis Optica Spectrum Disorders Elevation of AQP4 and selective cytokines in experimental autoimmune encephalitis mice provides some potential biomarkers in optic neuritis and demyelinating diseases.Immunoinflammatory diseases of the central nervous system - the tale of two cytokines.Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic.Upregulation of Bcl-2 and Its Promoter Signals in CD4+ T Cells during Neuromyelitis Optica Remission.

P2860

Q21146701-1452A7CA-ABD8-4EC6-AC72-5319EC564B4A Q21558554-FB0942A4-0B14-402C-B068-EAD64BAD8317 Q24598109-107914A7-794F-47E5-B886-0A8EA2395CAF Q24613666-7B55A7E7-97DE-48AC-B3B9-2BD7088F4AF8 Q26767391-C29C62E7-A0E6-43BF-8E50-435B93F39F6D Q26779177-CCE273C7-860B-42A1-93EA-F581571D23F4 Q26799789-84C85BCE-221D-4B4A-88EC-002F60F025A4 Q26999708-14326CA4-0B78-4437-9A03-EDE2AF99B5FE Q27021535-F05207F4-AD73-4B57-9667-14E10CD3C2C3 Q28245749-7CDE8CDF-AEF2-45E0-AD9B-C06752568280 Q30402227-A0FF8F35-7EBD-485F-B8EE-5A48794F8A97 Q30577078-E1715A17-D756-437A-8CC4-676EB8EA5AE8 Q30676331-1811DFD3-9C67-4A38-B1F0-820D9B0746B6 Q30785267-9AF9F050-4213-40E6-8256-1D55021021B5 Q30833332-C7E24617-112C-4ED5-9DE7-D1468ACCD552 Q30975717-E6BE02E6-F989-434A-BCC3-3251E6BF38CB Q33753860-1A1E6912-CE3A-49F9-AF01-790FF59AC2A5 Q33792739-419C4275-D5AB-47D7-A974-DEADC26B549B Q33862239-6BD64CA9-720F-4232-9401-3C91D4EDE50A Q34166367-B17F943E-071B-4B90-9013-488F2B27A9E5 Q34235490-E6109F55-A934-4EF3-A6A8-D32787ED41FF Q34248105-9304714A-E237-4E02-A3E5-303519CF0A53 Q34399291-5A35E0C4-F632-44B9-875E-C1E6756C0411 Q34919661-F16C3B82-A067-42B8-A9A3-CFE53D57B622 Q34976749-65CEC956-CC88-4284-8640-CAB1720288FF Q35052199-418D7459-D6C2-4659-805E-68EFE0819767 Q35067939-32EF5718-B60A-46DA-931D-EA3C3AF1E03D Q35077861-87CE2816-C6C7-4F1B-9DFA-35FFF8032F81 Q35120688-FE3DC395-D585-4E21-8598-524245E67417 Q35591039-54E93A82-CBFB-41AA-8B71-ED7987218948 Q35738898-76532BE8-4C66-4828-9D7B-56A081D2AFF6 Q35751397-2FC7809B-BF12-42DC-BFAA-9778272E138F Q35962565-5730E685-F8B4-414C-AF17-6F67E151E30C Q36348690-C9C692FC-7FE8-43A1-8CE7-75E5263939A4 Q36457613-B53F4CD1-4835-4603-8348-B4AECFABEF62 Q36484394-07311966-314B-4D6D-ABB2-10ECEA68B694 Q36511714-B734B5D2-A3D9-45E5-A6EE-547A9D7C31BA Q36547012-32AE95EE-514F-4466-9644-EBEFD11809F1 Q36727762-AF9C1F7F-4A9A-4522-A602-B872675BF0A2 Q37601388-7C077EF1-9DB7-4422-B0D2-A8E1900C650B

P2860

Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica.

http://www.wikidata.org/entity/Q34621516

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Interleukin 6 signaling promot ...... lasts in neuromyelitis optica.

@ast

Interleukin 6 signaling promot ...... lasts in neuromyelitis optica.

@en

Interleukin 6 signaling promot ...... lasts in neuromyelitis optica.

@nl

type

label

Interleukin 6 signaling promot ...... lasts in neuromyelitis optica.

@ast

Interleukin 6 signaling promot ...... lasts in neuromyelitis optica.

@en

Interleukin 6 signaling promot ...... lasts in neuromyelitis optica.

@nl

prefLabel

Interleukin 6 signaling promot ...... lasts in neuromyelitis optica.

@ast

Interleukin 6 signaling promot ...... lasts in neuromyelitis optica.

@en

Interleukin 6 signaling promot ...... lasts in neuromyelitis optica.

@nl

P1433

Q34621516-821FB27B-8DE3-4BE5-83C5-663F6EAFBD0E

P1476

Q34621516-6FA84833-59E7-4575-9056-120C0A67B627

P2093

Q34621516-2A3DC06B-C7B3-40BD-B593-538F8541C894

Q34621516-81ED84DE-877B-48DD-8F9A-F5D98C7237D5

Q34621516-AE492830-0572-42A6-A7DB-E09915A26A83

Q34621516-D918D5A3-F909-48EC-9CCB-140BE5D88341

Q34621516-DD5A8193-6BBA-4A9E-A8A1-5B1DDDB3A7C5

Q34621516-E81FF86B-5C78-4F74-BD92-726C4D601EED

Q34621516-F1C7DC72-6794-4B66-A231-B759EE92ED0D

Q34621516-FAA9825C-1EFD-4E09-B992-0662ADF92207

P2860

Q34621516-04B7854A-6D06-4AF1-BA10-F77270A18A30

Q34621516-1AE32E4D-B3C5-41CA-95E2-725AC3197872

Q34621516-1B7B164E-D6B4-48E8-8A34-42470BCFB42E

Q34621516-1F577EEE-C1AF-4BFE-B575-89F7508F5518

Q34621516-2D85A229-C67E-41DA-A4C4-98F201C6CB27

Q34621516-3F1CCE4A-C968-4C80-AB61-D01E6C5C603E

Q34621516-3F342192-98E1-4A54-A1D4-2D82FE3E73F3

Q34621516-4F977454-84FC-4413-832D-4C258175B1C0

Q34621516-51451E24-BFB0-4E37-BE08-AA47993CD56F

Q34621516-5DD8A65B-1E03-437F-A94D-21413181529E

P304

Q34621516-D6E163F1-6505-4323-A0D3-2B915F534093

P31

Q34621516-F558824F-EA6C-41E8-B998-164E2C89C57B

P356

Q34621516-CD84DCC7-E0C5-4748-9DEB-638C22E7E725

P407

Q34621516-65277DE6-3E21-4FE7-96CA-21174DEFBB00

P433

Q34621516-D75FBD8D-E7EC-4F25-91AC-06361C02DB6D

P478

Q34621516-F0D48CBB-EC23-41DC-B12B-C42E885707C5

P50

Q34621516-F7E95F29-13F8-4B1F-8CA4-090ED7E72059

P577

Q34621516-3271621C-0928-417C-8633-A24932350249

P5875

Q34621516-03938F2F-7F5D-4792-8012-2038CF94EC5E

P698

Q34621516-B25C3B5F-1C79-45FD-AA5E-B238BC70AAF1

P921

Q34621516-1c56ee5c-20bd-4ea7-8d42-728fe09bfd8f

Q34621516-8B441552-A9BE-4D43-A94A-CD16E7FD8A2A

P932

Q34621516-D4FDB454-6F46-4AA9-B55B-6765B337B783

P356

PNAS.1017385108

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Interleukin 6 signaling promot ...... blasts in neuromyelitis optica

@en

P2093

Masafumi Ogawa

http://www.w3.org/2001/XMLSchema#string

Sachiko Miyake

http://www.w3.org/2001/XMLSchema#string

Takashi Yamamura

http://www.w3.org/2001/XMLSchema#string

Tatsushi Toda

http://www.w3.org/2001/XMLSchema#string

Tomoko Okamoto

http://www.w3.org/2001/XMLSchema#string

Toshimasa Aranami

http://www.w3.org/2001/XMLSchema#string

Wakiro Sato

http://www.w3.org/2001/XMLSchema#string

Yusei Miyazaki

http://www.w3.org/2001/XMLSchema#string

P2860

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

Rapid cloning of high-affinity human monoclonal antibodies against influenza virus

Negative regulation of Toll-like receptor 4 signaling by the Toll-like receptor homolog RP105

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells

Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre.

The spectrum of neuromyelitis optica.

Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice.

Treatment of neuromyelitis optica: current debate.

Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease.

Revised diagnostic criteria for neuromyelitis optica.

P304

3701-3706

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.1017385108

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

108

http://www.w3.org/2001/XMLSchema#string

P50

P577

2011-02-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49836186

http://www.w3.org/2001/XMLSchema#string

P698

21321193

http://www.w3.org/2001/XMLSchema#string

P921

P932

3048150

http://www.w3.org/2001/XMLSchema#string